We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Adjuvant Chemotherapy for Resected Non Small-Cell Lung Cancer.
- Authors
Benjamin Solomon; John D. Mitchell; Paul A. Bunn
- Abstract
Because of the high rate of distant disease recurrence, the 5-year survival of patients who have undergone complete surgical resection of localized non-small-cell lung cancer (NSCLC) is approximately 50%. Initial results from early studies of adjuvant postoperative chemotherapy reported an adverse effect of alkylating agent and older chemotherapy regimens on survival. Cisplatin-based combinations were the first to show a survival advantage. A 1995 meta-analysis of these studies suggested a 13% reduction in the hazard ratio for death (HR = 0.87), leading to a 5% survival benefit at 5 years. Still, these trials involved limited numbers of patients (N = 1,394), and the results failed to reach statistical significance (P =.08). Of the five largest subsequent randomized trials of platinum-based adjuvant therapy, three showed a significant survival advantage. Although it is impossible to determine the reasons for the differing outcomes of these studies, several key features distinguish them, and the data suggest that medically fit patients with resected stage IB or H NSCLC should be offered chemotherapy with a platinum/new drug combination.
- Subjects
LUNG cancer; LUNG surgery; SURGICAL excision; POSTOPERATIVE care; DRUG therapy; ADJUVANT treatment of cancer
- Publication
Oncology (08909091), 2005, Vol 19, Issue 13, p1685
- ISSN
0890-9091
- Publication type
Article